ArticleInvestigative ophthalmology & visual science2025
6-Shogaol Alleviates Endotoxin-Induced Uveitis via Activation of HIF-1α to Regulate Inflammatory Responses and Endoplasmic Reticulum Stress.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research Progress on the Regulatory Role of Treg Cells in Inflammatory Eye Diseases.Current issues in molecular biology · 2026Review
- Benzyl isothiocyanate alleviates neural damage in experimental autoimmune uveitis by modulating the TREM-1/PI3K/AKT signaling pathway.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: 6-Shogaol (6-S) has demonstrated anti-inflammatory effects in various disease models; however, its effects in uveitis have not been investigated. This research intends to investigate the therapeutic mechanisms of 6-S in acute uveitis. Methods: An endotoxin-induced uveitis (EIU) mouse model was developed to assess the therapeutic potential of 6-S for uveitis. Disease severity was evaluated through anterior segment evaluation, clinical scoring, and pathology staining. RNA sequencing (RNA-seq) and network pharmacology explored the potential molecular mechanisms. In vitro, BV2 cells were stimulated by lipopolysaccharide. The mRNA and protein levels of pro-inflammatory cytokines, endoplasmic reticulum (ER) stress markers, and hypoxia-inducible factor 1-alpha (HIF-1α) in eyeballs and cells were detected. Transmission electron microscopy and Ca2+ levels were used to evaluate ER damage. The targeting effect of 6-S on HIF-1α was tested by HIF-1α siRNA. Results: 6-S alleviated EIU in mice. RNA-seq indicated that inflammatory pathways are potential mechanisms of 6-S treatment. Further results showed that 6-S inhibited the expression of pro-inflammatory cytokines in vivo and in vitro. Network pharmacology revealed that the effect of 6-S may related to the ER. 6-S downregulated GRP78, ATF4, and CHOP expression; suppressed PERK and IRE1α phosphorylation; and mitigated ER swelling and cellular Ca2+ overload. Moreover, 6-S upregulated the expression of HIF-1α in vivo and in vitro. Inhibiting HIF-1α largely eliminated the anti-inflammatory and relieving ER stress properties of 6-S. Conclusions: 6-S alleviates ER stress and inflammatory responses by modulating the expression of HIF-1α, thereby improving the prognosis of EIU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.